Investigation Report on China's Paclitaxel Market, 2010-2019

Description: When paclitaxel first came into the market, American Food and Drug Administration (FDA) only approved it to be used in the clinical treatment of advanced non-small cell cancer and advanced ovarian cancer. As paclitaxel rapidly becomes popular in the clinic over the next 20 years, at present it is utilized in the treatment of advanced breast carcinoma, prostatic cancer, Kaposi's sarcoma, head and neck cancer, cutaneous carcinoma and some other common malignant tumors. Ever since it came into the market in 1992, paclitaxel, the best-selling phytogenic anticarcinogen, has brought in an accumulated sales value of over USD 20 billion. Before 2000, 90% of the global paclitaxel market was dominated by Bristol-Myers Squibb Company. After the patent of paclitaxel expired, over 100 companies around the world were engaged in the production of APIs and preparations of paclitaxel.

China is one of the leading countries with diagnoses of cancer. In China 5 million to 6 million new cases of cancer are identified each year. However, the overwhelmingly high price of paclitaxel injection (CNY 1600 for one dose of paclitaxel injection in the past) has constrained its sale in the Chinese market. Therefore, the sale of paclitaxel in China has been poor in the past ten years. However, ever since Jiangsu Heng Rui Medicine Co., Ltd started to produce the APIs and preparations of Docetaxel, the situation of China lagging behind developed countries in the consumption of paclitaxel has changed. Since domestic paclitaxel injection is much cheaper than its imported counterpart, the formerly high-end medicine has truly become affordable to ordinary people. At present the market price for each dose of domestic paclitaxel injection (30mg/5ml) ranges from CNY 285 to CNY 550.

Annual sales value of paclitaxel in China has risen from less than CNY 400 million in 2005 to CNY 1,388 million in 2014, and its CAGR during the period of 2005-2014 was 17.3%. According to the market survey of CRI, leading enterprises in China paclitaxel market include Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd, The Department of Cancer, Bristol-Myers Squibb Company (U.S.), American Pharmaceutical Partners and Abraxis BioScience (U.S.), among which Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd took up over half of the market share in 2014.

As planted forests of Chinese yew increases, the output of paclitaxel in China is expected to keep growing.

It is estimated that the market size of paclitaxel in China will keep growing in the next few years.

Readers can have access to the following information through reading this report:
- market size of paclitaxel in China
- competitive landscape of paclitaxel in the Chinese market
- price of paclitaxel produced by different enterprises in China
- market outlook of paclitaxel in China

The author suggests the following groups of people purchase this report:
- manufacturers of antineoplastic drugs
- investors/research institutions interested in the Chinese medicine market

Contents: Table of Contents

1 Related Concepts of Paclitaxel
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Paclitaxel in China
2.1 Patent and Approval Status of Paclitaxel in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Paclitaxel in China, 2010-2014
3.1 Sales Value
3.1 Overall Sales Value
3.1.2 Sales Value By Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume By Regions

4 Survey on Market Share of Major Manufacturers of Paclitaxel in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Different Dosage Forms of Paclitaxel in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Prices of Paclitaxel in Chinese Hospitals in 2014
6.1 Abraxis BioScience, LLC (US) (Trade Name: Abraxane)
6.2 Hospira Australia Pty Ltd (AU)(Trade Name: Anzatax)
6.3 Wellso Pharmaceutical Co., Ltd
6.4 Beijing Union Pharmaceutical Co., Ltd
6.5 Beijing SL Pharmaceutical Co., Ltd
6.6 Harbin Pharmaceutical Group Bioengineering Co., Ltd (Trade Name: Paclitaxel Injection)
6.7 Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd
6.8 Shandong Lukang Cisen Pharmaceutical Co., Ltd
6.9 Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd (Trade Name: Paclitaxel Liposome for Injection)
6.10 Jiangsu Aosaikang Pharmaceutical Co., Ltd (Trade Name: Paclitaxel Injection)
6.11 Yangtze River Pharmaceutical Group
6.12 The Department of Cancer, Bristol-Myers Squibb Company (United States of America) (Trade Name: Taxol)

7 Major Manufacturers of Paclitaxel in Chinese Market, 2010-2014
7.1 Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd
7.2 Yangtze River Pharmaceutical Group
7.3 The Department of Cancer, Bristol-Myers Squibb Company
7.4 Jiangsu Aosaikang Pharmaceutical Co., Ltd
7.5 Shandong Lukang Cisen Pharmaceutical Co., Ltd

8 Market Outlook of Paclitaxel in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts
Chart Patent Status of Paclitaxel in China
Chart Approval Information of Paclitaxel in China
Chart Sales Status of Paclitaxel in Chinese Market, 2010-2014
Chart Sales Value of Paclitaxel in China, 2010-2014
Chart Sales Value of Paclitaxel in Some Regions of China, 2010-2014
Chart Sales Volume of Paclitaxel in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Paclitaxel for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Paclitaxel Produced by Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd in China, 2010-2014
Chart Sales Value and Market Share of Paclitaxel Produced by The Department of Cancer, Bristol-Myers Squibb Company in China, 2010-2014
Chart Sales Value and Market Share of Paclitaxel Produced by American Pharmaceutical Partners in China, 2010-2014
Chart Sales Value and Market Share of Paclitaxel Produced by Abraxis BioScience (US) in China, 2010-2014
Chart Sales Value and Market Share of Paclitaxel Produced by Yangtze River Pharmaceutical Group in China, 2010-2014
Chart Price of Paclitaxel Produced by Abraxis BioScience, LLC (US) in Some Cities of China in 2014
Chart Price of Paclitaxel Produced by Hospira Australia Pty Ltd (AU) in Some Cities of China in 2014
Chart Price of Paclitaxel Produced by Wellso Pharmaceutical Co., Ltd in Some Cities of China in 2014
Chart Price of Paclitaxel Produced by Beijing Union Pharmaceutical Co., Ltd in Some Cities of China in 2014
Chart Price of Paclitaxel Produced by Beijing SL Pharmaceutical Co., Ltd in Some Cities of China in 2014
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Investigation Report on China’s Paclitaxel Market, 2010-2019
- Web Address: http://www.researchandmarkets.com/reports/3308570/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy</td>
<td>USD 2000 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 3000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: ___________ Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
- First Name: ___________________________ Last Name: ___________________________
- Email Address: * ___________________________
- Job Title: ___________________________
- Organisation: ___________________________
- Address: ___________________________
- City: ___________________________
- Postal / Zip Code: ___________________________
- Country: ___________________________
- Phone Number: ___________________________
- Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World